Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Alumis Inc. Common StockNASDAQ: ALMS
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures declines year over year
Q2 FY2026 capital expenditures of $237K (cash outflow) fell 61.5% year over year, ahead of the -77.7% change in trailing-twelve-month capital expenditures. Sequentially, it rose 44.5% from the prior quarter. Over 3 fiscal years it compounded at -35.3% a year.
Context
- Capital expenditures amounted to 2.7% of revenue in FY2025.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -61.5% holds above the trailing-twelve-month pace of -77.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (653K) USD
- Year-over-year change
- +62.3%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (653K) | +62.3% |
| FY2024 | 2024-12-31 | (1.73M) | +61.5% |
| FY2023 | 2023-12-31 | (4.5M) | -87.0% |
| FY2022 | 2022-12-31 | (2.41M) | — |
Capital Expenditures vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -77.7% is the 5th highest of 7, against a peer median of +69.2%.
- Capital expenditures amounts to 5.4% of revenue for ALMS, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $2.32M USD | +104.2% | -25.7% | — |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $401K USD | -77.7% | -35.3% | 5.4% |
| LTM Mar 2026 | €114.87K EUR | +178.5% | -11.9% | 391.6% | |
| LTM Mar 2026 | $81K USD | -99.8% | -43.2% | 1.0% | |
| LTM Mar 2026 | $69K USD | -81.1% | -37.6% | 0.0% | |
| FY2025 | $21K USD | +38.3% | — | — | |
| LTM Mar 2026 | $4 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | +100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ALMS) | — | +69.2% | -31.6% | 0.0% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (111.93M) | (154.99M) | (294.23M) | (243.33M) |
| Depreciation & Amortization | 250K | 1.28M | 3.15M | 3.5M |
| Deferred Income Tax | 0 | 0 | 0 | (8.56M) |
| Stock-Based Compensation | 5.96M | 8.63M | 19.46M | 43.52M |
| Change in Working Capital | (1.92M) | 12.06M | 14.76M | 26.32M |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.29M | (642K) | 8.51M | (6.04M) |
| Other Working Capital | (3.21M) | 12.7M | 6.25M | 32.35M |
| Other Non-Cash Items | (86K) | 3.05M | 1.79M | (190.98M) |
| Operating Cash Flow | (107.72M) | (129.98M) | (255.08M) | (369.52M) |
| Capital Expenditures | (2.41M) | (4.5M) | (1.73M) | (653K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (209.08M) | (11.28M) | (240.06M) | (209.17M) |
| Sales of Investments | 142.73M | 76.25M | 128M | 447.96M |
| Other Investing Activities | 0 | 0 | 0 | 49.74M |
| Investing Cash Flow | (68.75M) | 60.47M | (113.79M) | 287.88M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 193.32M | 2.08M |
| Common Stock Repurchased | 0 | 0 | 0 | (17K) |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.73M | (96K) | 40.59M | 0 |
| Financing Cash Flow | 101.63M | 89.68M | 492.37M | 2.07M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (74.85M) | 20.18M | 123.5M | (79.58M) |
| Free Cash Flow | (110.13M) | (134.47M) | (256.81M) | (370.18M) |
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.